Clinical Trials Logo

Clinical Trial Summary

A nationwide multicenter open label randomized controlled non-inferiority trial, including 18 departments. The study aims to compare an individualized antibiotic treatment duration with standard seven days of antibiotic treatment for culture negative early-onset infection in term newborns.


Clinical Trial Description

There is a documented antibiotic overuse in newborns, and a lack of evidence for the optimal duration of antibiotic therapy in culture-negative infection. The study aims to evaluate the effect of individualized treatment duration in early-onset infection. The study aims to compare an individualized treatment duration with seven days of treatment for culture negative early-onset infection. The investigators hypothesize that the individualized treatment duration, based on structured clinical assessment of symptoms and level of CRP is non-inferior to the standard care being seven days of treatment. In the experimental treatment arm, antibiotics will be stopped when the participant had 24 hours without symptoms and at same time point have decreasing level of CRP, with an absolute threshold of CRP ≤ 30 mg/l. The investigators hypothesize that individualized treatment will shorten the duration of antibiotic therapy in newborns with early onset infection with very little risk of relapse. Newborns who fulfill criteria to stop antibiotics within 48 hours will not be eligible for inclusion. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05329701
Study type Interventional
Source Rigshospitalet, Denmark
Contact Emma Malchau Carlsen, MD,PhD
Phone +4527380508
Email emma.louise.malchau.carlsen@regionh.dk
Status Recruiting
Phase Phase 4
Start date April 22, 2022
Completion date April 18, 2028

See also
  Status Clinical Trial Phase
Recruiting NCT04081792 - Optimal Antibiotics for Operated Diabetic Foot Infections N/A
Recruiting NCT05499481 - Short Against Long Antibiotic Therapy for Infected Orthopedic Sites Phase 3
Recruiting NCT05950984 - Medical Device (MD) Derived Pharmacokinetic (PK) Parameters for Vancomycin (MD-PK)
Completed NCT03199911 - Topical Antibiotic Prophylaxis for Eyelids Phase 4
Completed NCT05355571 - The Impact of Probiotic Supplementation on Antibiotic Induced Changes in Gastrointestinal Function and/or Faecal Microbiota Composition N/A
Recruiting NCT05699174 - PO vs IV Antibiotics for the Treatment of Infected Nonunion of Fractures After Fixation Phase 3
Completed NCT03087890 - Impact of Cotrimoxazole Use in Immunocompetent HIV Patients on Carriage of Antimicrobial Resistant Bacteria Phase 4
Completed NCT01254097 - Probiotics in Primary Care N/A
Recruiting NCT06018792 - Molecular Culture for the Diagnosis of Pediatric Sepsis
Completed NCT06030713 - Timing of Maternal Antibiotic Prophylaxis During a Cesarean Section and the Early Infant Gut Microbiome N/A
Active, not recruiting NCT05027893 - Complications After Lower Third Molar Surgery N/A
Not yet recruiting NCT03935828 - Effect of Topical Sinonasal Antibiotics Phase 2
Not yet recruiting NCT06383637 - Antibiotic Use and Resistance KAP Among Dental Interns
Enrolling by invitation NCT04707092 - Use of Preoperative and Postoperative Antimicrobial Treatment Phase 4
Recruiting NCT03932708 - Improving Antibiotic Use in Urgent Care Facilities N/A
Recruiting NCT04731025 - Local Antibiotics for Breast Implants Phase 3
Completed NCT04403334 - Postoperative Safety Outcomes of Intraoperative Intracameral Preservative-Free Moxifloxacin Versus Levofloxacin Phase 4
Completed NCT04127682 - Antibiotic Prescription for Children With Acute Upper Respiratory Tract Infections in Assiut District
Completed NCT05742295 - Prevention of Cefoperazone-induced Coagulopathy Phase 4
Not yet recruiting NCT06250413 - Autoflor -Lyophilized Capsulated Autological FMT to Restore Gut Microbiome After Treatment With Antibiotics N/A